June 15, 2022 -- Thermo Fisher Scientific is offering its Direct Mass Technology mode to enable simultaneous charge detection for analysis of previously unmeasurable analytes. The company contends the mass spectrometry solution will provide proteomics and biopharmaceutical laboratories working in drug discovery and R&D applications with the ability to decipher complex mixtures of large macromolecules.
The Direct Mass Technology mode augments Thermo Fisher's Q Exactive Ultra High Magnification Radiography (UHMR) Hybrid Quadrupole-Orbitrap mass spectrometers with charge detection capabilities, enabling direct mass determination of hundreds to thousands of individual ions in a single spectrum. With this capability, laboratories will be able to measure mass for complex heterogeneous mixtures of multiple charged components, providing insights into proteoforms, biotherapeutics, and next-generation drug modalities, according to the company.
"Direct Mass Technology mode combines charge detection with our trusted high-resolution accurate mass Orbitrap measurements to achieve results unattainable by current ensemble measurement techniques," said Iain Mylchreest, vice president of research and development, analytical instruments at Thermo Fisher Scientific. "By dissolving the complexity barriers inherent to other approaches, we're enabling a wealth of investigations that were once firmly out of reach -- from resolving heavily modified proteoforms to revealing small changes in large antibody-drug conjugate complexes, to name but a few."